Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG -6.4%) dips after missing Q1 estimates on all counts despite solid sales growth and better margins. Net earnings actually jumped 57% Y/Y on strong sales of its flagship blood-cancer treatment Revlimid. Separately, the company says it's entered into a strategic partnership with privately held Epizyme to develop personalized therapies for patients with genetically defined cancers.